全文获取类型
收费全文 | 5315篇 |
免费 | 307篇 |
国内免费 | 29篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 61篇 |
妇产科学 | 107篇 |
基础医学 | 640篇 |
口腔科学 | 71篇 |
临床医学 | 459篇 |
内科学 | 1700篇 |
皮肤病学 | 138篇 |
神经病学 | 559篇 |
特种医学 | 87篇 |
外科学 | 572篇 |
综合类 | 9篇 |
一般理论 | 4篇 |
预防医学 | 479篇 |
眼科学 | 41篇 |
药学 | 284篇 |
中国医学 | 12篇 |
肿瘤学 | 413篇 |
出版年
2024年 | 3篇 |
2023年 | 23篇 |
2022年 | 65篇 |
2021年 | 149篇 |
2020年 | 70篇 |
2019年 | 145篇 |
2018年 | 176篇 |
2017年 | 108篇 |
2016年 | 107篇 |
2015年 | 121篇 |
2014年 | 207篇 |
2013年 | 333篇 |
2012年 | 520篇 |
2011年 | 441篇 |
2010年 | 284篇 |
2009年 | 254篇 |
2008年 | 373篇 |
2007年 | 449篇 |
2006年 | 382篇 |
2005年 | 341篇 |
2004年 | 303篇 |
2003年 | 252篇 |
2002年 | 213篇 |
2001年 | 31篇 |
2000年 | 25篇 |
1999年 | 28篇 |
1998年 | 43篇 |
1997年 | 39篇 |
1996年 | 27篇 |
1995年 | 29篇 |
1994年 | 23篇 |
1993年 | 19篇 |
1992年 | 9篇 |
1991年 | 9篇 |
1990年 | 12篇 |
1989年 | 2篇 |
1988年 | 4篇 |
1987年 | 4篇 |
1986年 | 3篇 |
1985年 | 4篇 |
1984年 | 4篇 |
1983年 | 3篇 |
1982年 | 3篇 |
1981年 | 2篇 |
1980年 | 5篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1953年 | 1篇 |
1948年 | 1篇 |
排序方式: 共有5651条查询结果,搜索用时 15 毫秒
51.
The associations between psychotic experiences and substance use and substance use disorders: findings from the World Health Organization World Mental Health surveys
下载免费PDF全文
![点击此处可从《Addiction (Abingdon, England)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Louisa Degenhardt Sukanta Saha Carmen C. W. Lim Sergio Aguilar‐Gaxiola Ali Al‐Hamzawi Jordi Alonso Laura H. Andrade Evelyn J. Bromet Ronny Bruffaerts José Miguel Caldas‐de‐Almeida Giovanni de Girolamo Silvia Florescu Oye Gureje Josep M. Haro Elie G. Karam Georges Karam Viviane Kovess‐Masfety Sing Lee Jean‐Pierre Lepine Victor Makanjuola Maria E. Medina‐Mora Zeina Mneimneh Fernando Navarro‐Mateu Marina Piazza José Posada‐Villa Nancy A. Sampson Kate M. Scott Juan Carlos Stagnaro Margreet Ten Have Kenneth S. Kendler Ronald C. Kessler John J. McGrath 《Addiction (Abingdon, England)》2018,113(5):924-934
52.
53.
54.
Lluis Asmarats François Dagenais Elisabeth Bédard Sergio Pasian Rebecca T. Hahn José L. Navia Josep Rodés-Cabau 《The Canadian journal of cardiology》2018,34(10):1370.e5-1370.e7
Despite the growing evidence with emerging transcatheter tricuspid valve repair therapies, the experience with transcatheter tricuspid valve replacement remains sparse. We describe a case of severe tricuspid regurgitation in a 79-year-old patient deemed unsuitable for isolated tricuspid valve surgery, successfully treated with a 40-mm self-expandable NaviGate (NaviGate Cardiac Structures, Inc, Lake Forest, CA) valved stent via a transatrial approach, with excellent result and hemodynamic performance at 4 months. 相似文献
55.
Andrew X. Zhu Richard S. Finn Yoon-Koo Kang Chia-Jui Yen Peter R. Galle Josep M. Llovet Eric Assenat Giovanni Brandi Kenta Motomura Izumi Ohno Bruno Daniele Arndt Vogel Tatsuya Yamashita Chih-Hung Hsu Guido Gerken John Bilbruck Yanzhi Hsu Kun Liang Ryan C. Widau Chunxiao Wang Paolo Abada Masatoshi Kudo 《British journal of cancer》2021,124(8):1388
Background Post hoc analyses assessed the prognostic and predictive value of baseline alpha-fetoprotein (AFP), as well as clinical outcomes by AFP response or progression, during treatment in two placebo-controlled trials (REACH, REACH-2).Methods Serum AFP was measured at baseline and every three cycles. The prognostic and predictive value of baseline AFP was assessed by Cox regression models and Subpopulation Treatment Effect Pattern Plot method. Associations between AFP (≥ 20% increase) and radiographic progression and efficacy were assessed.Results Baseline AFP was confirmed as a continuous (REACH, REACH-2; p < 0.0001) and dichotomous (≥400 vs. <400 ng/ml; REACH, p < 0.01) prognostic factor, and was predictive for ramucirumab survival benefit in REACH (p = 0.0042 continuous; p < 0.0001 dichotomous). Time to AFP (hazard ratio [HR] 0.513; p < 0.0001) and radiographic (HR 0.549; p < 0.0001) progression favoured ramucirumab. Association between AFP and radiographic progression was shown for up to 6 (odds ratio [OR] 5.1; p < 0.0001) and 6–12 weeks (OR 1.8; p = 0.0065). AFP response was higher with ramucirumab vs. placebo (p < 0.0001). Survival was longer in patients with an AFP response than patients without (13.6 vs. 5.6 months, HR 0.451; 95% confidence interval, 0.354–0.574; p < 0.0001).Conclusions AFP is an important prognostic factor and a predictive biomarker for ramucirumab survival benefit. AFP ≥ 400 ng/ml is an appropriate selection criterion for ramucirumab.Clinical Trial Registration ClinicalTrials.gov, REACH () and REACH-2 ( NCT01140347).Subject terms: NCT02435433Oncology, Biomarkers 相似文献
56.
Feliciano Villar Montserrat Celdran Josep Fabà 《Gerontology & geriatrics education》2014,35(2):171-181
The goals of this study were to determine the learning impact of an assignment that consisted of interviewing and analyzing older people’s life stories, and to explore how the assignment was evaluated by students. Participants in the study were 122 first-year social education students enrolled in an adult development and aging course. They evaluated the assignment using an eight-adjective questionnaire and were asked about the benefits of the task. Their answers to the questionnaire were then reviewed using content analysis. The results indicated that marks on the life story assignment predicted marks on an exam about basic course concepts. Students considered that the assignment was interesting, useful, and integrated into the course, although most of them also thought that it was very time-consuming. They identified benefits related to the explicit goals of the course (improvement in the learning of developmental concepts, the acquisition of research-related skills, and the deactivation of aging stereotypes) and personal, growth-related benefits. The authors discuss the difficulties posed by the assignment and its usefulness as a complement to more traditional, lecture-based teaching methods in adult development and aging courses. 相似文献
57.
58.
Ximena Terra PhD Teresa Auguet MD PhD Zaida Agüera MSc Isabel Maria Quesada Josep Maria Orellana‐Gavaldà PhD Carmen Aguilar PhD Susana Jiménez‐Murcia PhD Alba Berlanga MSc Esther Guiu‐Jurado MSc José Manuel Menchón MD Fernando Fernández‐Aranda PhD Cristóbal Richart MD PhD 《The International journal of eating disorders》2013,46(8):855-861
59.
Gemma Mayor-Subirana José Yagüe-García Eduard Valmaseda-Castellón Josep Arnabat-Domínguez Leonardo Berini-Aytés Cosme Gay-Escoda 《Medicina oral, patología oral y cirugía bucal》2014,19(2):e192-e201
Objectives: To evaluate the efficacy of Oraqix® during scaling and root planing (SRP) in comparison with 20% benzocaine and placebo.
Study Design: 15 patients requiring 4 sessions of SRP were enrolled. For each patient, Oraqix®, Hurricaine®, vaseline or no anesthetic product were randomly assigned each to a quadrant. Treatment pain was evaluated on a 100 mm Visual Analog Scale (VAS) and on a Verbal Rating Scale (VRS). The amount of product administered, the need to re-anesthetise, patient and operator satisfaction and the onset of side-effects were also recorded.
Results: Oraqix® was significantly better than nothing, with a reduction of VAS score to 13.3 units, but without significant differences with Vaseline or Hurricaine®. Oraqix® was better in VRS reduction than not using any anesthetic (p=0.001) or using vaseline (p=0.024), but similar to Hurricaine® (p=0.232).
Conclusions: Oraqix® effectively controls pain in SRP procedures, with few side-effects and a good acceptance on the part of patients and clinicians.
Key words:Controlled clinical trial, topical anesthetic, scaling and root planing. 相似文献
60.